Coronary In-stent Restenosis
6
0
0
2
Key Insights
Highlights
Success Rate
100% trial completion (above average)
Treatment Research
8 treatments under study, led by Taxus Liberte
Research Leaders
20 sponsors active, led by Terumo Medical Corporation
Clinical Risk Assessment
Based on trial outcomes
Moderate Risk
Score: 30/100
0.0%
0 terminated out of 6 trials
100.0%
+13.4% vs benchmark
50%
3 trials in Phase 3/4
0%
0 of 2 completed with results
Key Signals
Data Visualizations
Phase Distribution
Trial Status
Trial Success Rate
Benchmark: 86.6%
Based on 2 completed trials
Clinical Trials (6)
A Safety and Efficacy Study of Dissolve™ in Treatment of Coronary In-stent Restenosis
Evaluation of the Efficacy and Safety of a Paclitaxel Eluting PTCA Balloon Catheter in Coronary In-stent Restenosis
Retrospective Long-term Safety and Efficacy Study of the Beta-Cath(TM) 3.5F System
Restenosis Intrastent: Bioresorbable Vascular Scaffolds Treatment With Scoring Balloon Pre-dilatation (RIBS VI Scoring)
Restenosis Intrastent: Bioresorbable Vascular Scaffolds Treatment (RIBS VI)
A Safety and Efficacy Study of Paclitaxel-eluting Balloon to Paclitaxel-eluting Stent
Research Network
Common Treatments
- Taxus Liberte1
- Bioresorbable Vascular Scaffold Absorb Gt1 Abbott1
- Dissolve1
- Sequent Please Paclitaxel Eluting Balloon1
- Bioresorbable Vascular Scaffold1
Active Sponsors
- Terumo Medical Corporation2
- Instituto de Investigación Sanitaria Hospital Universitario de la Princesa2
- Abbott Medical Devices2
- Spanish Society of Cardiology2
- Fundación de Investigación Biomédica - Hospital Universitario de La Princesa2
Top Investigators
Medstar Health Research Institute
Chinese Academy of Medical Sciences, Fuwai Hospital
Fuwai CVD Hospital of Chinese Academy of Medical Sciences